Abnormalities of the endolysosomal and autophagy systems are found in Alzheimer's disease, but it is not clear whether defects in these systems are a cause or consequence of degenerative processes in the disease. In human neuronal models of monogenic Alzheimer's disease, APP and PSEN1 mutations disrupt lysosome function and autophagy, leading to impaired lysosomal proteolysis and defective autophagosome clearance. Processing of APP by g-secretase is central to the pathogenic changes in the lysosome-autophagy system caused by PSEN1 and APP mutations: reducing production of C-terminal APP by inhibition of BACE1 rescued these phenotypes in both APP and PSEN1 mutant neurons, whereas inhibition of g-secretase induced lysosomal and autophagic pathology in healthy neurons. Defects in lysosomes and autophagy due to PSEN1 mutations are rescued by CRISPR-knockout of APP. These data demonstrate a key role for proteolysis of the C-terminal of APP by g-secretase in neuronal dysfunction in monogenic Alzheimer's disease.
INTRODUCTION
Abnormalities of the endolysosomal and autophagy systems are both found in Alzheimer's disease (AD) (Nixon, 2017; Lie and Nixon, 2018) . Prominent enlargement of endosomal compartments precedes the appearance of neurofibrillary tangles and neuritic plaques in mouse models of AD (Cataldo et al., 2000) . Similarly, selective accumulation of lysosomal dense bodies and autophagic vacuoles in dystrophic neurites has been observed in post-mortem brain samples of people with AD (Nixon et al., 2005) , suggesting that autolysosomal proteolysis is impaired in AD (Nixon, 2017) . Genome-wide association studies have identified SNPs in several genes with roles in the endolysosomal and autophagy systems as impacting disease risk, including PICALM, CLU, SORL1, ABCA7, and BIN1 (Karch and Goate, 2015) . These underscore the significance of the endolysosomal and autophagy systems as a genetic risk hotspot in AD (Nixon, 2017) . However, it is not clear whether defects in lysosomal and autophagic systems are a cause or consequence of degenerative processes in AD.
Collectively, genetic data place APP processing by g-secretase as central to disease initiation in monogenic forms of AD, including familial AD due to PSEN1 and APP mutations (Selkoe, 2002) . The majority of known familial AD mutations are autosomal dominant and affect the amyloid precursor protein (APP) gene or the catalytic components of the g-secretase APPprocessing complex, presenilin (PSEN) 1 and 2 (Bertram and Tanzi, 2008) . As well as missense mutations, increased APP gene dosage due either to trisomy of chromosome 21 (Ts21) or duplication of the APP locus (APP (dup)) also leads to early onset AD (Rovelet-Lecrux et al., 2006) . Conversely, a protective mutation near the BACE-cleavage site in APP has been identified that reduces the risk of developing dementia (Jonsson et al., 2012) .
How changes in APP processing by g-secretase lead to AD is still not well understood. Deposition of amyloid beta (Ab) peptide fragments of the amyloid precursor protein (APP) in amyloid plaques and hyperphosphorylated tau in neurofibrillary tangles are the cellular hallmarks of AD (O'Brien and Wong, 2011) . The amyloid hypothesis proposes that it is the accumulation of extracellular toxic forms of Ab as both soluble oligomers and insoluble plaques that is the primary pathologic driver of the disease (Hardy and Selkoe, 2002) . However, causal links between production of potentially toxic longer forms of Ab peptides, amyloid deposition, and disease initiation have not been definitively demonstrated and remain contentious (De Strooper and Karran, 2016) . Nascent APP proteins mature through the constitutive secretory pathway from endoplasmic reticulum and the Golgi apparatus and are transported to the plasma membrane (Thinakaran and Koo, 2008) . Endosomal and lysosomal compartments are involved in APP processing and perturbation of the endolysosomal system can lead to altered APP processing, Ab peptide production and amyloid accumulation (Nixon, 2017) . Conversely, increased expression of APP or expression of mutant APP in fibroblasts leads to dysfunction of the endolysosomal system (Cataldo et al., 2008) . AD mutations in PSEN1 lead to altered lysosomal function, including reduced acidification through altered PSEN1-mediated recruitment of the Vo ATPase to the lysosome, which in turns leads to defects in neuronal macroautophagy (Lee et al., 2010) . Moreover, PSEN1 deficiency has been shown to alter lysosomal calcium storage and release (Coen et al., 2012; Neely Kayala et al., 2012) . While the appearance of pathological changes in the endolysosomal and autophagy systems is an important early feature of AD, whether these changes are causes or consequences of primary drivers of neurodegenerative processes remain unclear (Peric and Annaert, 2015) .
To address this question, we investigated how AD mutations in APP and PSEN1 affect the endolysosomal and autophagy systems in human-stem-cell-derived cortical neurons. We and others have previously shown that mutations in APP and PSEN1 lead to immediate changes in APP processing, with either increased relative or absolute amounts of longer forms of Ab peptides (Yagi et al., 2011; Muratore et al., 2014; Moore et al., 2015) . We now find that mutations in both APP and PSEN1 causal for monogenic, early onset AD, lead to major defects in lysosome function and autophagy in induced pluripotent stem cell (iPSC)-derived human neurons, with APP mutations also disrupting endosomal function. Reducing production of C-terminal APP by inhibition of BACE1 rescued these phenotypes in both APP and PSEN1 mutant neurons, and defects in the lysosomal and autophagic systems due to PSEN1 mutations are prevented by CRISPR knockout of APP. These data demonstrate that compromised proteolysis of the C-terminal of APP by g-secretase by autosomal dominant mutations in both PSEN1 and APP causes dysfunction of the endolysosomal and autophagy systems in human neurons and is a driver of neurodegeneration in familial AD.
RESULTS

AD Mutations in APP, but Not PSEN1, Result in Early Endosome Abnormalities in Human Cortical Neurons
To study the effects of AD mutations in APP and PSEN1 on the neuronal endolysosomal system, we generated cortical excitatory neurons from iPSCs derived from individuals with genetic changes or mutations causal for AD: APP V717I, trisomy chromosome 21 (Ts21), APP duplication (APPdup), and three different PSEN1 mutations (Y115C, M146I, and Intron 4). Neurons were generated according to our previously described methods (Shi et al., 2012a) and confirmed as being cortical in neuronal identity by both gene expression and immunofluorescence (Figures S1A-S1C). As we previously described (Moore et al., 2015) , both PSEN1 and APP missense mutations increase the proportion of longer forms of Ab relative to shorter forms, as reflected in reduced Ab40:Ab42 ratios, whereas APPdup and Ts21 neurons overproduce all measured forms of Ab peptides ( Figures S1D-S1G ).
Endosomes are highly active processing sites for APP, and accumulation of enlarged early endosomes and lysosomes in neurons has been observed in post-mortem brain samples of patients with sporadic AD and some forms of familial AD (Cataldo et al., 2000 (Cataldo et al., , 2001 Colacurcio et al., 2018; Nixon, 2017) . Using a GFP fusion of the small Rab GTPase Rab5A to visualize early endosomes, we observed significantly enlarged Rab5A-positive early endosomes in neurons with missense mutations in APP or increased copy number of APP (APPdup and Ts21), compared with those in control neurons ( Figures 1A and 1B) . Moreover, the number of enlarged early endosomes per neuron was increased significantly in both APP duplication and missense mutation neurons ( Figure 1C ). This was accompanied by upregulation of the total mass of early endosomes, as reflected in an increase in endogenous Rab5A protein levels ( Figures 1D and 1E) .
In contrast, endosomal number and size, as measured by imaging and western blot levels of Rab5, were unchanged in neurons with each of three PSEN1 mutations (M146I, Y115C, and Intron 4). However, levels of the lysosomal protein LAMP1 were increased in both APP and PSEN1 Y115C or M146I mutant neurons ( Figures 1D and 1F ), indicating that both classes of mutations share defects in late endosomes and/or lysosomes.
Accumulation of Enlarged Late Endosomes and
Lysosomes in Human Neurons with PSEN1 or APP Mutations To further investigate potential defects in the lysosomal system, we studied late endosomes and/or lysosomes in human cortical neurons with mutations in APP and PSEN1 by live imaging. The number and size of lysosomes was increased in monogenic AD neurons of each genotype (APP and PSEN1 mutations, Ts21), with the exception of PSEN1 Intron 4 neurons (Figures 2A-2C ). Neurons with APP or PSEN1 mutations had accumulations of clustered lysosomes in their cell bodies (Figure 2A ). In addition, the average size (area) of lysosomes in APP and PSEN1 mutant neurons was significantly larger than that of control neurons (Figure 2B) . This difference in average lysosome size was due to a change in the distribution of lysosome sizes within mutant neurons, whereby mutant neurons contained a population of very large lysosomes, together with a set of lysosomes of the same size as those in control neurons ( Figure 2B ). To confirm that LAMP1 expression does not alter lysosome size, we examined the size of LAMP1 + vesicles by either expression of RFP-tagged LAMP1 (live cell) or immunostaining for endogenous LAMP1 (fixed cell) in control neurons. We observed a very similar size distribution profile using either method ( Figures S2A and S2B ). Furthermore, we analyzed the size of endogenous LAMP1 + vesicles in control and APP V717I neurons. Consistent with our data using RFP-tagged LAMP1, we observed a significant increase in the size of endogenous LAMP1 in APP mutant neurons compared with control ( Figures S2C and S2D ). The lack of detectable differences in lysosomal biology at this early stage in PSEN1 Intron4 neurons is surprising, given that these neurons have similar changes in Ab peptide production as the other PSEN1 mutant neurons ( Figure S1 ). However, the molecular nature of the PSEN1 Intron4 mutation is qualitatively different from the majority of PSEN1 mutations, which are missense protein-coding mutations that result in single amino acid substitutions (De Jonghe et al., 1999) , and may enable some degree of compensation by the more abundant wild-type form of PSEN1 at these stages in relatively young neurons.
Impaired Axonal Lysosome Transport and Proteolysis
Deficits in Human APP and PSEN1 Mutant Neurons Given the accumulation of abnormally large lysosomes in the cell bodies of APP and PSEN1 mutant neurons, we measured axonal transport of lysosomes in human familial AD neurons and controls. Axonal trafficking of lysosomes was quantified using time-lapse microscopy of axons in a microfluidic device, with lysosomes labeled with a fluorescent dye that preferentially identifies acidic organelles (LysoTracker). We observed that LysoTracker-positive vesicles were concentrated near the somatodendritic region ( Figure S3 ). Furthermore, to prove that LysoTracker-positive structures are functional lysosomes, we treated LysoTracker-stained neurons with glycyl-L-phenylalanine-b-naphthylamide (GPN), which is a substrate of lysosomal protease cathepsin C that triggers osmotic lysis of lysosomes after cleavage. We observed that cleavage of GPN by cathepsin C diminished fluorescence of LysoTracker-positive organelles, confirming that they are lysosomes ( Figure S4 ). For this and subsequent analyses, the PSEN1 Intron4 mutation was not included, given the lack of endosome, lysosome, and autophagy phenotypes.
Consistent with previous reports of similar assays (Hung and Coleman, 2016) , lysosomal movements were observed in both anterograde and retrograde directions in these neurons (Figure 3A) . Moreover, the average size of axonal lysosomes was significantly increased in APP or PSEN1 (M146I and Y115C) mutant neurons ( Figure 3B) . Analyses of the rates of lysosomal transport revealed that APP or PSEN1 (M146I and Y115C) mutations reduced the numbers of moving lysosomes ( Figure 3C ). Furthermore, this reduction was seen in both anterograde and retrograde directions ( Figure 3C ).
Lysosomes accumulating within the distal ends of swollen axons in mouse models of AD contained low levels of multiple luminal lysosomal proteases (Gowrishankar et al., 2015) , including cathepsin D (CatD). To investigate CatD activation within lysosomes in control and monogenic AD neurons, we live-imaged axons co-labeled with LysoTracker and BODIPY-FL-pepstatin A, which binds selectively to active CatD (Chen et al., 2000) . To analyze the extent of co-migration between lysosomes and activated CatD, kymographs were generated for each Number of vesicles per unit cytoplasmic area (C) was measured in three independent experiments (n = 3), with total numbers of cells indicated within each bar. (D-F) Representative western blots of Rab5A, LAMP1, and neuron-specific b3-tubulin in three independent control and AD neurons are shown (D). Levels of Rab5A (E) and LAMP1 (F) were calculated relative to b3-tubulin from three independent experiments (n = 3), including an independent neural induction in each case. Error bars, SEM. See also Figure S1 .
channel (GFP and RFP) and for their overlays ( Figure 3D ). We then quantified the extent of co-migration in the axon by comparing pairs of kymographs generated for each channel ( Figure 3E ). In control neurons, over 60% of the lysosomes contained activated CatD ( Figure 3E ). However, fewer than 40% of the lysosomes in monogenic AD neurons contained activated CatD ( Figure 3E ).
Defective Degradation of Autophagosomes in Human
APP and PSEN1 Mutant Neurons Impaired lysosomal clearance can be associated with additional changes in autophagy, including accumulation of autophagic vesicles (Lie and Nixon, 2018) . Therefore, we carried out a number of studies of autophagy in human familial AD neurons. To assess autophagosome size, we expressed an RFP-fusion of the autophagy receptor p62/SQSTM1 in neurons of each genotype and measured the size of p62/SQSTM1-positive autophagic vesicles in control and monogenic AD neurons ( Figure 4A ). We observed a striking accumulation of enlarged p62-positive autophagosomes in both APP and PSEN1 mutant neurons compared to control neurons, indicating impairment in autophagy (Figures 4A and 4B) . Given the dynamic nature of autophagy, we measured autophagic flux in control and monogenic AD neurons to quantify autophagosome synthesis and degradation, using a previously reported quantitative approach ( Figure 4C ) (Rubinsztein et al., 2009) . To do so, we treated neurons with the mitochondrial respiratory chain uncoupler (CCCP) to activate autophagy by triggering the loss of mitochondrial membrane potential ( Figure 4C ). The degradative phase of autophagy was blocked by v-ATPase inhibition with bafilomycin A1 (Baf A 1 ) in either the presence or absence of autophagy induction by CCCP ( Figure 4C ). Western blot analysis of the relative amounts of LC3-I and LC3-II among the different conditions (with and without CCCP, with and without Baf A 1 ) enabled the measurement of both the synthetic and degradative phases of autophagy ( Figure 4C ) (Rubinsztein et al., 2009) .
Autophagy was induced in both control and monogenic AD neurons by CCCP treatment, as demonstrated by significant upregulation of LC3-II in the presence of CCCP and Baf A 1 compared with neurons treated with Baf A 1 alone ( Figure 4D ). However, comparing neurons treated with CCCP to induce autophagy with those treated with CCCP and Baf A 1 (blocking autophagosome degradation) found a further elevation of LC3-II levels only in control neurons but not in the different AD neurons, indicating an impairment of autophagosome degradation in monogenic AD neurons (Figures 4D and 4E) .
We confirmed that the degradative phase of autophagy is compromised in familial AD neurons using an alternative mTORindependent autophagy inducer, the Akt inhibitor 10-(4 0 -(N-diethylamino) butyl)-2-chlorophenoxazine hydrochloride (10-NCP) (Tsvetkov et al., 2010) . As seen with autophagy induction by mitochondrial stress with CCCP, autophagy induction with 10-NCP followed by inhibition of the vATPase with Baf A 1 did not result in a further increase in LC3-II levels in familial neurons ( Figures  4D and 4F) . As with CCCP-induced autophagy, familial AD neurons demonstrated defective autophagy degradation when autophagy was induced by Akt inhibition ( Figures 4D and 4F ).
Gamma-Secretase Inhibition Disrupts Function of the Lysosomal-Autophagic System in Human Neurons
Previous studies have suggested that intraneuronal accumulation of the C terminus of APP (APP-CTF) is a consequence of impaired lysosomal-autophagic degradation, rather than a cause of lysosome or autophagy dysfunction (Peric and Annaert, 2015) . Processing of APP by BACE1 in the endosome generates the 99 amino acid C-terminal fragment of APP (b-CTF), which is in turn a substrate for g-secretase in the lysosome. We observed a significant increase in APP-b-CTF levels in both APP and PSEN1 mutant neurons compared to control neurons ( Figures 5A-5C ). To further investigate the consequences of accumulation of b-CTF on the lysosomal and autophagy systems in non-diseased control neurons, we used small molecule inhibitors of g-secretase to prevent turnover of b-CTF ( Figure 5D ). As expected, inhibition of either g-or b-secretase significantly reduced extracellular Ab peptides ( Figure 5E ), and g-secretase inhibition led to a marked accumulation of b-CTF ( Figure 5F ).
Inhibition of g-secretase led to an increase in both LAMP1 protein and LC3-II levels in healthy control neurons ( Figure 5F ). Together with the increase in LAMP1 protein levels, there was a significant increase in the number of enlarged lysosomes in neurons following g-secretase inhibition ( Figures 5G and 5H) . Furthermore, g-secretase inhibition led to an accumulation of LC3-positive autophagosomes, with g-secretase inhibition markedly increasing the number and size of the GFP-LC3 puncta in neurons ( Figures 5G and 5I ). In addition, live imaging of axonal transport of lysosomes found that lysosome transport was significantly impaired in neurons following g-secretase inhibition ( Figures 5J-5L ). Inhibition of g-secretase led to both an increase in stationary lysosomes within axons, as well as a reduction in both retrograde and anterograde lysosome transport ( Figures  5J-5L ). Furthermore, we observed a significant reduction in the percentage of lysosomes that contained CatD-positive signals in healthy control neurons treated with GSI ( Figure 5M ). To investigate whether the observed autophagosome accumulation was caused by induction of autophagy or by inhibition of degradation, we measured autophagic flux as described above ( Figure 4C ). In contrast with familial AD neurons, we found that autophagosome synthesis was increased following either b-secretase or g-secretase inhibition ( Figures  5N and 5O ). However, whereas degradation was not changed following b-secretase inhibition, g-secretase inhibition significantly reduced autophagosome degradation ( Figure 5P ). These data indicate that reducing g-secretase turnover of C terminus of APP leads to lysosomal-autophagic dysfunction, suggesting that the turnover of the C terminus of APP by g-secretase has a regulatory role in modulating the lysosomal-autophagy system.
Dysfunction in the Lysosome-Autophagy System in Familial AD Neurons Is Reversed by b-Secretase Inhibition
Given that inhibition of APP-CTF turnover by g-secretase negatively impacted the lysosomal-autophagy system in healthy neurons, we investigated the effect of manipulating APP processing on lysosome-autophagy defects in AD neurons. We focused on addressing whether reducing the production of b-CTF by inhibition of b-secretase would ameliorate autophagy defects in monogenic AD neurons (PSEN1 and APP mutations, trisomy 21).
As expected, inhibition of b-secretase activity significantly reduced the production of total APP-bCTF levels ( Figure 6A ) and total extracellular Ab peptides in neurons of all genotypes ( Figure 6B ). We observed that manipulation of b-secretase activity alters LAMP1 expression in genetic forms of AD ( Figure S5 ). In addition, there was a significant reduction in the size of p62/SQSTM1-positive vesicles in familial AD and trisomy 21 neurons, suggesting that b-secretase inhibition corrected defects in the degradative phase of autophagy ( Figures 6C and  6D) . Measurements of autophagic flux in monogenic AD neurons treated with b-secretase inhibitor were performed using the same methods as described above. As indicated by the imaging of p62-RFP, b-secretase inhibition led to a significant increase of the degradation phase of autophagy compared to vehicletreated neurons of each genotype (Figures 6E-6G ).
Autophagy Defects in PSEN1 Mutant Neurons Are
Rescued by CRISPR Knockout of APP While the pharmacological manipulation of both BACE1 and g-secretase strongly implicated APP in mediating PSEN1-dependent phenotypes, they do not formally prove this. To investigate this, we used CRISPR genome engineering to knockout both alleles of APP in PSEN1 Y115C iPSCs ( Figure 7A ). Cortical neurons generated from two independent clones of PSEN1 Y115C;APP À/À iPSCs had no detectable production of extracellular Ab peptides ( Figures 7B and 7C ), confirming the complete absence of APP. Deletion of APP in PSEN1 Y115C neurons reduced LAMP1 protein levels ( Figure 7C ) and increased the axonal transport of lysosomes ( Figures 7D and 7E ), compared with isogenic PSEN1 Y115C neurons. Removal of APP also rescued autophagy defects in PSEN1 Y115C neurons. There was a significant reduction in the size of p62-RFP positive vesicles in the APP knockout neurons, compared with isogenic PSEN1 Y115C neurons ( Figures 7F and 7G ). Measuring autophagic flux in isogenic PSEN1 Y115C and PSEN1 Y115C;APP À/À neurons demonstrated that removal of APP protein rescued the impairment in the degradative phase of autophagy seen in PSEN1 Y115C neurons ( Figures 7H and 7I) . Therefore, these data demonstrate that the lysosomal-autophagy defects observed in PSEN1 mutant neurons are APP-dependent. (B) CRISPR targeting of both alleles of APP was confirmed by the complete absence of extracellular Ab peptides generated by PSEN1 Y115C;APP knockout (KO) neurons, compared with isogenic PSEN1 Y115C neurons. Multiplexed ELISA quantification of extracellular Ab peptides from unedited and two independent clones of APP KO neurons from three independent experiments (n = 3). (C) APP protein was not detected in two independent clones of PSEN1 Y115C; APP KO neurons, confirming complete knockout of both APP alleles. In contrast, total LAMP1 levels are decreased in two independent clones of PSEN1 Y115C;APP KO neurons (90 days post-neural induction), compared with unedited PSEN1 Y115C neurons (two-tailed t test between unedited and KO neurons). Representative western blots of APP, LAMP1, b-actin, and neuron-specific b3-tubulin unedited isogenic PSEN1 Y115C and two independent clones of PSEN1 Y115C;APP KO neurons. (D and E) Live imaging of iPSC-derived neurons labeled with 100 nM LysoTracker Red DND-99 (D). Scale bar, 10 mm. Significant increases in the number of moving lysosomal vesicles (E) in two independent clones of PSEN1 Y115C;APP KO neurons, compared with unedited isogenic PSEN1 Y115C neurons (two-tailed (legend continued on next page)
DISCUSSION
We report here that mutations in APP and PSEN1 that are causal for early onset AD lead to major defects in lysosome function and autophagy in human neurons. The rapid appearance of these defects indicates that they are a direct effect of those mutations, and not a secondary consequence of a primary degenerative process, such as protein aggregation. Consistent with this, we find that inhibition of g-secretase causes lysosomal and autophagy dysfunction in healthy human neurons. APP and PSEN1 mutant neurons accumulate APP-b-CTF and reducing production of C-terminal APP by inhibition of BACE1 rescued lysosome-autophagy phenotypes in both APP and PSEN1 mutant neurons. Defects in the lysosome and autophagy systems due to PSEN1 mutations are prevented by CRISPR knockout of APP, demonstrating that lysosome and autophagy dysfunction in PSEN1 mutant neurons are dependent on the presence of APP. These data demonstrate that compromised proteolysis of the C-terminal of APP by g-secretase by autosomal dominant mutations in PSEN1 and APP causes dysfunction of the lysosomal and autophagy systems in human neurons and represents a potential driver of neurodegeneration in monogenic AD. We and others have previously reported that neurons generated from iPSCs with genetic forms of AD recapitulate aspects of the disease, including increased Ab peptide production in trisomy 21 and APP duplication neurons (Moore et al., 2015; Israel et al., 2012) and increased production of longer forms of Ab in PSEN1 and APP mutant neurons (Moore et al., 2015; Muratore et al., 2014; Woodruff et al., 2016; Israel et al., 2012) . We now report that AD mutations in APP and PSEN1 converge on disruption of the lysosome and autophagy system in human neurons. Given growing evidence from genome-wide association studies implicating the endolysosomal and autophagy systems in AD risk (Karch and Goate, 2015) , these data suggest that dysfunction in these systems may represent an early pathogenic process in the disease.
The contributions of the endolysosomal and autophagy systems to AD initiation and progression are currently unclear, with debate surrounding whether observed defects in those systems are causes or consequences of neuronal dysfunction and neurodegeneration (Nixon, 2017) . Post-mortem analyses of the cerebral cortex have demonstrated enlarged early endosomes in neurons of individuals with trisomy 21 or APP duplication (Cataldo et al., 2000) , as well as in transgenic mouse models expressing human APP, trisomy 21 fibroblasts, and various cell lines overexpressing different forms of APP (Nixon, 2017) . Focal axonal swellings containing accumulations of lysosomal dense bodies and autophagic vacuoles have been observed in postmortem brain samples of Alzheimer's patients (Nixon, 2013 (Nixon, , 2017 Nixon et al., 2005) , suggesting a failure of their axonal transport.
We have found that mutations in APP and PSEN1 converge on defects in lysosome function and autophagy. The presence of these changes within relatively young neurons, combined with the ability to induce these phenotypes by acute gammasecretase inhibition, indicates that these defects are a direct consequence of mutations in APP and PSEN1, and not an indirect effect of another degenerative process, such as protein aggregation. PSEN1 mutant neurons do not have early endosome defects, in contrast with APP mutant neurons. This is consistent with previous analysis from post-mortem studies showing that early endosomal abnormalities were not found in individuals with either PSEN1 or PSEN2 mutations, despite Ab overproduction and amyloid plaque deposition (Cataldo et al., 2000) . In addition, endosomal dysfunction was also absent in both primary fibroblasts from patients with PSEN1 mutation and neurons from PS1 and bAPP transgenic mice (Cataldo et al., 2000) . Our finding that the different APP and PSEN1 mutations overlap in lysosome and autophagosome dysfunction suggest that the primary site of action of these mutant proteins is the lysosome, with endosomal changes being a secondary effect.
Processing of APP by BACE1 in the endosome generates the APP C-terminal fragment (APP-b-CTF), which is in turn a substrate for g-secretase in the lysosome. The role of APP-CTF in AD pathogenesis is the subject of considerable debate. Previous studies have suggested that intraneuronal accumulation of APP-CTF is a consequence of impaired lysosomal-autophagic degradation, rather than a cause of endolysosome or autophagy dysfunction (Peric and Annaert, 2015) . In addition, a recent study showed that deletion of APP expression in mice deficient for all g-secretases, by deletion of the genes encoding Aph1 subunits, failed to rescue progressive neurodegeneration (Acx et al., 2017) . In that case, there was a general accumulation of many g-secretase substrates, due to complete loss of g-secretase function, which is in contrast to the hypomorphic character of autosomal dominant pathogenic mutations in PSEN1 (Moore et al., 2015; Chá vez-Gutié rrez et al., 2012) . Recent studies, however, have reported that intraneuronal aggregation of APP-CTF induced Ab-independent lysosomal-autophagic pathology (Lauritzen et al., 2016; Jiang et al., 2016) . We found that increasing intracellular APP-CTF by g-secretase inhibition induced lysosomal-autophagic pathology: elevated levels of lysosomal LAMP1 and autophagosome LC3-II, increased t test between unedited and KO neurons). Axons were measured in three independent experiments, with total numbers of axons (n) indicated within each bar. density and size of LC3-positive puncta, and increased number of enlarged LAMP1-positive vesicles. In addition, g-secretase inhibition markedly impaired axonal transport of lysosomes and led to autophagic defects. Conversely, we find that dysfunction in lysosomal-autophagy system observed in human APP and PSEN1 mutant neurons can be reversed by b-secretase inhibition, which reduces the supply of APP-b-CTF to the late endosome and/or lysosome (Jiang et al., 2010) . These data argue that accumulation and/or altered turnover of APP-CTF by g-secretase lead to dysfunction in the neuronal lysosomal-autophagy system. Importantly, the rescue of lysosomal-autophagy defects by CRISPR deletion of APP in a PSEN1 mutant background formally demonstrates that those defects are dependent on APP protein, and not simply convergent independent phenotypes due to mutations in either gene.
The lack of detectable defects in lysosome and autophagosome function in PSEN1 Intron4 neurons is surprising, given that these neurons have similar changes in Ab peptide production as the other PSEN1 mutant neurons. However, the molecular nature of the PSEN1 Intron4 mutation is qualitatively different from the majority of PSEN1 mutations, which are missense protein-coding mutations that result in single amino acid substitutions (De Jonghe et al., 1999) . The PSEN1 Intron4 mutation is a single base deletion within the splice donor site, which has been predicted to generate three different final mRNAs, two of which encode truncated forms of PSEN1, and the third includes an extra amino acid (De Jonghe et al., 1999) . If this is the case in cortical neurons, the relative amounts of wild-type and full-length mutant PSEN1 proteins would be much less than 1:1, and relatively higher levels of the wild-type form of PSEN1 might enable short-term compensation for the deleterious effects of the mutant protein. Therefore, it will be essential to further study the effects of this mutation on lysosome and autophagosome function over longer time frames and in neurons homozygous for this mutation.
The early stage of axonal lysosome biogenesis is thought to begin in distal regions of axons with the merging of organelles derived from endocytic and autophagic pathways (Maday and Holzbaur, 2014) . Further maturation of lysosomes requires retrograde transport to the cell soma where luminal proteases can be delivered from the trans-Golgi network efficiently (Maday et al., 2012) . Such a mechanism allows neurons to effectively remove autophagic cargos from axon terminals and synapses. We found that AD mutations in APP and PSEN1 markedly disrupted the axonal transport of lysosomes and those lysosomes accumulate within distal axons contained low levels of cathepsin D. This is similar to previous findings in human AD brain tissue as well as various AD mouse models in which focal axonal swellings containing accumulations of lysosomal dense bodies and autophagic vacuoles have been observed (Nixon, 2017) .
Although autophagy activation may be a promising therapeutic strategy for AD, its beneficial role in disease pathogenesis is not clear. Several studies showed that increasing autophagy in mouse models of AD ameliorates amyloid pathologies and memory deficits (Spilman et al., 2010; Yang et al., 2011) . However, autophagy induction has also been reported to activate the amyloidogenic pathway and increase Ab secretion Nilsson et al., 2013) . Similarly, administration of rapamycin after the formation of amyloid plaques failed to rescue the cognitive deficits in mouse model of AD (Majumder et al., 2011) . Our data suggest that induction of autophagy may become counterproductive in the face of impaired transport of axonal lysosomes, lysosomal clearance deficits and reduced autophagosome degradation, by further overburdening the already failing lysosomes and thus exacerbating autophagic accumulation in axons. Indeed, recent studies have demonstrated that restoring retrograde transport of autophagic vacuoles by overexpressing Sanpin proteins successfully reduced AD-associated autophagic stress (Tammineni et al., 2017) . The present study on human cortical neurons provides further evidence that either reducing input of APP to the lysosomal-autophagy system, enhancing axonal transport or augmenting lysosome function at the early disease stages may represent potential therapeutic strategies to attenuate autophagic defects in AD. Overall, this study establishes a foundation for future investigation into cellular pathways enhancing autophagy and lysosomal proteolytic activity as an approach to ameliorating neurodegeneration in AD.
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